This Little Piggy

As a former biotech/pharma business development guy and now amateur observer of global health matters, I am out of my depth when commenting on the economics and policy of health care provision and financing.  But I try to do it anyway, primarily because, from my naïve view point, a potential and potent first step to [...]

Affordability Revisited

Two postings ago (October 14), I noted that Cipla, the billion-dollar Indian generic pharma company, is developing affordable versions of biological anti-cancer drugs and that it likely assumes there will be some type of scheme to pay for the drugs.  [Sidebar:  Pfizer closed a multimillion dollar deal for diabetes bio-similars last week with another Indian [...]

Affordability

At the August annual meeting of Cipla, a major India-based generic drug company, YK Hamied, the chairman, noted the company is extending its generics business model to biological drugs, aka  “biosimilars” or “bio-betters,” in part through a $200 million dollar investment in building a biologics plant (Business Standard article).  Further he said, “We believe this [...]